Further subclassification of the AML cell panel identified additional biomarkers besides FHIT that could potentially modulate the response to DCPS inhibition, including mutations in DNMT3A and FLT3 internal tandem duplications (ITD) [5] (Fig. 1D). This evidence concerns the gene DNMT3A and acute myeloid leukemia.